AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis

AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis

Abstract Novel treatment options for metastatic renal cell carcinomas (RCC) include specific MET inhibitors, GAS6/AXL inhibitors, and SRC inhibitors. The interplay between c‐MET, SRC, AXL expression, and their gene mutation patterns in different renal carcinoma subtypes is unclear. To improve the un...

Full description

Saved in:
Bibliographic Details
Main Authors: Muriel D Brada, Tülay Karakulak, Peter Schraml, Martina Haberecker, Dorothea Rutishauser, Jeffrey S Ross, Daniel Eberli, Holger Moch
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:The Journal of Pathology: Clinical Research
Subjects:
renal cell carcinoma
gene expression
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/2056-4538.70028
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/2056-4538.70028

Similar Items